David G Maloney
Overview
Explore the profile of David G Maloney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
243
Citations
14765
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Portuguese A, Huang J, Jeon Y, Taheri M, Albittar A, Liang E, et al.
Haematologica
. 2025 Mar;
PMID: 40079097
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy...
2.
Samples L, Sadrzadeh H, Frigault M, Jacobson C, Hamadani M, Gurumurthi A, et al.
Blood
. 2025 Feb;
PMID: 39938007
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 CAR T-cell therapy outcomes in patients...
3.
Gauthier J, Liang E, Huang J, Kimble E, Hirayama A, Fiorenza S, et al.
Blood Adv
. 2025 Jan;
PMID: 39820359
CD19-directed chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy elicits high response rates but fails to induce durable responses in most adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia...
4.
Liang E, Huang J, Portuguese A, Ortiz-Maldonado V, Albittar A, Wuliji N, et al.
Blood Adv
. 2024 Dec;
9(3):606-616.
PMID: 39626349
Immune effector cell-associated hematotoxicity (ICAHT) is associated with morbidity and mortality after chimeric antigen receptor (CAR) T-cell therapy. To date, the factors associated with ICAHT are poorly characterized, and there...
5.
Jaeger-Ruckstuhl C, Specht J, Voutsinas J, MacMillan H, Wu Q, Muhunthan V, et al.
Clin Cancer Res
. 2024 Oct;
31(3):503-514.
PMID: 39466024
Purpose: The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is expressed in hematopoietic and epithelial cancers but has limited expression on normal adult tissues. This phase I study evaluated the...
6.
Hirayama A, Wright J, Smythe K, Fiorenza S, Shaw A, Gauthier J, et al.
Hemasphere
. 2024 Aug;
8(8):e142.
PMID: 39113729
CD19-targeted chimeric antigen receptor T-cell (CAR-T) immunotherapy has transformed the management of relapsed/refractory large B-cell lymphoma (LBCL), yet durable remissions are observed in less than half of treated patients. The...
7.
Lozachmeur A, Danek T, Yang Q, Rosasco M, Welch J, Go W, et al.
NPJ Precis Oncol
. 2024 Aug;
8(1):174.
PMID: 39103508
To enable interrogation of tumor HLA LOH as a clinical diagnostic for precision oncology, we developed and validated an assay that detects HLA LOH within the context of an FDA-approved...
8.
Pullarkat S, Black G, Bleakley M, Buenrostro D, Chapuis A, Hirayama A, et al.
PLoS One
. 2024 Jun;
19(6):e0303057.
PMID: 38843256
As adoptive cellular therapies become more commonplace in cancer care, there is a growing need to monitor site-specific localization of engineered cells-such as chimeric antigen receptor T (CAR-T) cells and...
9.
Mo G, Lee S, Coffey D, Voillet V, Kirsch I, Gottardo R, et al.
Blood Cancer Discov
. 2024 May;
5(4):258-266.
PMID: 38747505
Chimeric antigen receptor (CAR) T-cell therapy produces high response rates in refractory B-cell non-Hodgkin lymphoma, but long-term data are minimal to date. In this study, we present long-term follow-up of...
10.
Krakow E, Brault M, Summers C, Cunningham T, Biernacki M, Black R, et al.
Blood
. 2024 Apr;
144(10):1069-1082.
PMID: 38683966
Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific...